Our LatestBlog & News
Dr Garcia joins the Redenlab science team to drive its language analytics pipeline for cognitive-linguistic disorders like fronto-temporal dementia.
Redenlab’s latest iOS application provides state of the art audio capture, storage and analysis of speech and language data for monitoring brain health.
Redenlab is contributing to a study sponsored by the Australian Department of Defence and The University of Melbourne on speech biometrics and decision making in submariners
Dr Amir Lahav hired as Chief of Digital Health and Strategy. He is a clinical neuroscientist and a leading innovator in digital health with a special focus on developing and validating novel biomarkers and AI-driven technology for remote monitoring of patients with neurodegenerative diseases.
What are the evidence-based recommendations to guide early intervention in children aged 0 to 2 years who have or are at high risk of cerebral palsy?
Redenlab presenting at upcoming INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS
Subtle differences in speech timing, vocal effort, and voice quality were found between cannabis and control groups. After controlling for lifetime alcohol and tobacco use, the cannabis group presented with longer and more variable pauses across tasks, and vocal effort was different compared to controls. Vocal effort and intensity also appeared to change in line with duration of abstinence from cannabis use – that is, they appeared get better the longer they stayed away from the drug. The differences observed between users and controls may reflect longer term changes to the underlying neural control of speech.
Dr Geoff Stuart joins the Redenlab analytics team as Statistics Director. Geoff will be running the company’s clinical trials statistics program and data analytics development. He brings expertise in mathematical statistics and a background in experimental psychology.
Redenlab are part of a successful consortium securing funding for training a new cohort of early career researchers in understanding key issues in optimal ageing (including environmental, social and economic factors that underlie health and independence in ageing).
Redenlab pediatric specialist Prof Angela Morgan co-authors a new study on speech models in minimally verbal children with autism spectrum disorder. The collaboration with scientists from Boston and Melbourne provides preliminary evidence that subphenotypes of children with MV ASD may exist.
Redenlab Inc. are pleased to announce securing clinical trial in Cyclic Vomiting Syndrome with a Top 10 pharma company. Redenlab are providing audio capture and analytics for a Phase 1b clinical trial. Conducted in sites across the USA, the study will investigate the long-term efficacy of a treatment designed to ameliorate the impact of this rare and debilitating disease.
Acoustic features that predict healthy aging are different than those previously reported for the pathologic voice. We propose a model of healthy and pathologic voice development in which voice characteristics are mediated by the inability to monitor vocal productions associated with age-related hearing loss.
Miglustat is currently the only approved disease-specific treatment shown to be effective in stabilizing neurological symptoms. Miglustat has previously been reported to halt or improve early dysphagia and cognitive symptoms. Here we examine the characteristics of dysphagia, the relationship between dysphagia and the presence of cognitive impairment, and longitudinal changes in swallowing function during miglustat treatment in adult-and-adolescent-onset NPC.
Redenlab CSO contributes to a new book chapter on the Best practices for supervised machine learning when examining biomarkers in clinical populations has been included in ‘Big Data in Psychiatry & Neurology’ published by Elsevier.
Professor Angela Morgan has been recognised for her outstanding leadership in advancing the diagnosis, prognosis and management of childhood speech disorders.
FOXP1-related disorder is characterized by a complex speech and language phenotype with prominent dysarthria, broader motor planning and programming deficits, and linguistic-based phonological errors. Diagnosis of the speech phenotype associated with FOXP1-related dysfunction will inform early targeted therapy.
Redenlab CSO, Adam Vogel, will be presenting at the upcoming ERN-RND joint webinar with the European Acadamy of Neurology and ERN EURO-NMD: Speech as a biomarker in Ataxia: What can it tell us & how should we use it?
SpeechATAXIA is a multi-language, multi-national, multi-ataxia consortia designed to measure communication change over time.
Redenlab are proud to support an upcoming randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia
Welcome Dr Noffs. Gustavo brings a wealth of clinical and research experience to the team, making contributions to tech development and science promotion, with a focus on his specialties of Parkinson’s disease and Multiple Sclerosis.
Published in the European Journal of Human Genetics we expand the linguistic phenotype associated with SETBP1 LoF syndrome (SETBP1 haploinsufficiency disorder), revealing a striking speech presentation that implicates both motor (CAS, dysarthria) and language (phonological errors) systems, with CAS (80%) being the most common diagnosis.
Redenlab Inc. are excited to announce securing another clinical trial in Friedreich ataxia. Redenlab are providing speech analytics for a long-term open label extension clinical trial. Conducted in 8 sites across the USA over 2 years, the study will investigate the long-term efficacy of a treatment designed to ameliorate the debilitating impact of this fatal disease. For the study, Redenlab will provide advanced speech recording and analysis solutions.
Redenlab Inc, the speech neuroscience company delivering insights in speech and language testing, announces that it has been selected by medium sized USA pharmaceutical company to support their upcoming gene therapy study in Friedreich ataxia (FA). Conducted across 5 sites in 3 countries over 2 years, the Phase 2a study will investigate the safety, tolerability and efficacy of gene therapy on adolescents with FA. For the study, Redenlab will provide advanced speech recording and analysis solutions.
Hardware selection is a an important and often overlooked aspect of speech research
Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.
Redenlab are proud to be supporting PTC Therapeutics, Inc. Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia.
Learn more about the platforms and applications that Redenlab use for software development, documentation, and quality management that is in-line with standards such as FDA 21 CFR Part 22.
We are excited to announce that Redenlab Speech Scientists ranked top 1 AND 2 in the world for dysarthria (most common neuromuscular speech disorder)!
Redenlab has entered into a 5 year collaboration with investigators from North and South America, Australia and Europe to investigate the underlying neural mechanisms of Friedreich ataxia. The study is supported by the Friedreich's Ataxia Research Alliance (FARA) and pharmaceutical industry partners.
Describing the relationship between disease severity and speech metrics, through listener-based and objective acoustic analysis.
In our new study, published in the Journal of Acoustical Society of America, we tested reliability, stability, and sensitivity to change in vowel measurements.
Article highlights
-
Dysarthria, a neuromuscular speech disorder, can be the first and most prominent manifestation of PD.
-
Alongside changes in speech, PD is associated with impaired morphosyntactic, lexical-semantic, and high-level language comprehension and production.
-
Pharmaceutical and surgical interventions for PD may improve certain modalities of speech production, but effects vary between individuals.
-
Longitudinal research designs are needed to evaluate the complex interplay between motor speech, language, and cognition.
-
Speech acoustics may serve as a valuable proxy marker of PD ‘risk’, disease progression and treatment efficacy.
Highlights
•Subtle but apparently genuine changes in speech occur in HD before clinical diagnosis.
•Speech changes in prodromal individuals are largely characterised by timing deficits.
•Limited longitudinal data restricts capacity to predict HD evolution using speech.
Highlights
•Measurable changes detected in swallowing function in 12 months
•Decline in function observed at three anatomical sites considered important for safe swallowing
•Individual anatomical sites may be precursors to widespread functional decline in swallowing